

Special Issue

Nature's Vanguard: Secondary Metabolites and Their Emerging Role in the Evolution of Cancer Therapy

Message from the Guest Editors

This Special Issue aims to consolidate current advances at the chemistry–biology interface of secondary metabolites and cancer research. By integrating approaches from natural product chemistry, molecular oncology, and systems pharmacology, we seek to identify new leads, elucidate mechanistic insights, and inspire rational drug design based on nature's molecular scaffolds. In doing so, the issue aspires to reaffirm the value of secondary metabolites as dynamic agents in the evolution of cancer therapeutics, from bench to bedside.

Guest Editors

Dr. Thiago André Moura Veiga

Department of Chemistry, Federal University of São Paulo, Diadema 09972-270, SP, Brazil

Prof. Dr. Edgar Julian Paredes-Gamero

Faculty of Pharmaceutical Sciences, Food and Nutrition, Federal University of Mato Grosso do Sul, Campo Grande 79070-900, Brazil

Deadline for manuscript submissions

30 April 2026



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



mdpi.com/si/248025

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPplus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).